



FOR IMMEDIATE RELEASE

KLOTHO Therapeutics Named One of San Diego Venture Group's 2017 COOL Companies

*Klotho Protein Found Naturally in Humans Offers a Road Map to Longevity,
Biotech Company to Create Patent-pending Klotho.*

San Diego, CA, June 5, 2017 – San Diego Venture Group (SDVG) honors KLOTHO Therapeutics, Inc. (KTI), one of the year's most exciting start-ups, for its biotech innovation that could redefine society's experience with aging. Klotho, a naturally occurring human protein discovered in 1997, has great potential to influence longevity, cognition and kidney function as well as slowing progression of diabetes and cancer. KTI has filed patents on modified Klotho proteins and plans to enter future human trials focused on one of many potential indications: kidney failure.

The name Klotho comes from the mythological Greek goddess Klotho, responsible for spinning the thread of life. It's an appropriate name as Klotho protein is involved in many biological pathways with both human and animal data supporting its effects. For example, National Institutes of Health report Klotho-deficient animals live 25% shorter and look older while animals overexpressing Klotho live 20-30% longer. Klotho also has the potential to delay major diseases of aging – kidney failure, Alzheimer's, osteoporosis, cancer, hypertension and diabetes, according to published studies.

KLOTHO Therapeutics' first focus is kidney failure, one of the major causes of death in the U.S. that affects up to 30 million people per year, 600,000 of whom are currently on dialysis. Today, there is no successful long-term therapy. KLOTHO founder/chairman Jim Plante has personal experience with kidney disease and is unwavering in his commitment to find a solution.

"Our work to help people live longer, healthier lives can have the same kind of societal impact that Jonas Salk had when he invented the polio vaccine in 1955," said Jim Plante, a serial entrepreneur who manages a portfolio of twelve companies under Thynk Capital (thynkcapital.com). "Imagine if someone like me could have Klotho therapy to slow or even reverse kidney damage – and avoid dialysis. We have the potential to redefine longevity. That's life-changing."

Not only is KTI's raison d'etre breaking new ground, but the way the company is handling development is as well. With no employees, KTI's virtual business model redirects the 40% overhead a typical biotech spends to accelerate development and human trials, which the company is well positioned to begin in two years.

As part of the COOL awards, KTI is invited to be a part of SDVG's Venture Summit on August 30, 2017, the largest annual gathering of VCs outside Silicon Valley.

About KLOTHO Therapeutics

KLOTHO Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to delay diseases of aging and help people live well longer. Naturally occurring in humans and animals, Klotho positively influences longevity, cognition and kidney function as well as slowing progression of diabetes and cancer. KTI is a virtual company led by successful biotech startup executives, headquartered in San Diego, California. For more information, please visit: www.klotho.com.

Contact: Bill Ramage, bill@klotho.com

###